These abstracts are a roadmap for delivering change at the intersection of clinical decision-making, operational efficiency, and financial sustainability.

The stakes have never been higher in oncology care. Rapid scientific breakthroughs, evolving regulatory demands, and mounting financial pressures are converging.

The 2025 Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx), to be held September 5–6 in Boston, will confront these challenges head-on through 13 powerful abstracts that demonstrate what it takes to translate evidence into action.

These abstracts are a roadmap for delivering change at the intersection of clinical decision-making, operational efficiency, and financial sustainability. Collectively, they reinforce a central CPC+CBEx 2025 message: transforming oncology care requires a unified approach that blends evidence-based treatment pathways, innovative technology, sustainable business models, and a commitment to equitable, high-quality care.

Submissions came from Radiation Business Solutions, Duke University Fuqua School of Business, Shields Health Solutions, AbbVie, Flatiron Health, US Oncology Network, Evolent, and Georgia Cancer Center at Augusta University.

These works span business strategy, infrastructure innovation, outcomes measurement, and treatment optimization — the very pillars that CPC+CBEx and the Journal of Clinical Pathways champion.

Accepted Abstracts for CPC+CBEx 2025

• Ensuring Access to Care: Using Tax-Exempt and Taxable Bond Funding for Consolidation of Outpatient Specialties (Business)
  Radiation Business Solutions, a not-for-profit entity funded through bond market financing, addressed financial instability in four independent community cancer centers in Alaska, preserving local ownership, access, and market stability.
• From Fragmented to Integrated: A Roadmap to Equity for Psychosocial Support in Rural and Underserved Cancer Programs (Business)
  Calls for integrating mental health services into oncology to improve adherence and quality of life for underserved populations.
• Pharmacist-Driven Outcomes for Patients on Oral Oncology Medications: Clinical Impact of an Integrated Specialty Pharmacy Model (Outcomes Measurement)
  This abstract shows how health system specialty pharmacies improve adherence and reduce adverse events in oral oncology care.
• Cost-Effectiveness Evaluation of BTKi Treatments Among Medicare Patients With CLL (Business + Treatment)
  AbbVie compares ibrutinib, acalabrutinib, and zanubrutinib cost-effectiveness to guide economically sound decisions.
• Enhancing Oncology Documentation and Diagnosis Capture with Integrated AI Scribe (Infrastructure & Innovation)
  Demonstrates how AI in OncoEMR by Flatiron Health improved efficiency, diagnosis capture, and clinician satisfaction.
• Streamlining Clinical Decision Support Through Integrated Education (Infrastructure & Innovation)
  Embeds point-of-care references in Clear Value Plus^TM to reduce care interruptions.
• Provision of Comparative Clinical Evidence to Support Pathway Decision Making (Outcomes Measurement)
  The Pathways Task Force introduces evidence tables with patient-reported outcomes to support transparent and informed pathway decisions.
• Green Light, Red Flags: A New Framework for Evaluating Oncology Accelerated Approvals (Infrastructure & Innovation)
  Evolent proposes metrics to assess FDA accelerated approvals and improve accountability.
• From Approval to Action: Evaluating Review Timelines for Oncology Therapies in Value Pathways (Infrastructure & Innovation)
  Examines rapid integration of FDA approvals and NCCN updates into value pathways.
• Decision Support Documentation for Targeted Therapy Eligibility in Breast Cancer (Treatment)
  Uses point-of-care prompts to improve biomarker documentation and therapy selection, following NCCN Guidelines recommendations.
• Modification of PARP Inhibitor Use in mCRPC With BRCA1/2 and MSI-H Status (Treatment)
  Updates pathways to favor pembrolizumab for certain genetic profiles over PARP inhibitors.
• Assessing Clinical Pipe, EHR to EDC Data Transfer Solutions (Infrastructure & Innovation)
  Finds automated EHR-to-EDC transfer improves trial accuracy and efficiency.
• Efficacy, Safety, and End-of-Treatment Mutational Results From the 5-Year OPTIC Study (Treatment)
  Supports a response-adjusted ponatinib dosing strategy in CP-CML with strong long-term outcomes.

Why It Matters for Pathways Innovators, Clinicians, and Business Leaders

Providers attending CPC+CBEx 2025 will gain a strategic playbook for delivering high-value, equitable cancer care. By combining pathway-driven clinical rigor, workflow innovation, and sustainable business planning, these abstracts offer solutions that can be implemented immediately after the meeting.

Event Details

• Clinical Pathways Congress + Cancer Care Business Exchange (CPC+CBEx) 2025
• September 5–6, 2025
• Boston, Massachusetts
• Event Website
• Registration Details
• Accepted Abstracts